Skip to main content
ViroGates A/S logo

ViroGates A/S — Investor Relations & Filings

Ticker · VIRO ISIN · DK0061030574 LEI · 5493007TX8XS56RMZD94 ST Manufacturing
Open in API
Filings indexed 162 across all filing types
Latest filing 2020-04-14 Regulatory Filings
Country DK Denmark
Listing ST VIRO

About ViroGates A/S

https://www.virogates.com/

ViroGates A/S is an in-vitro diagnostics company that develops and markets blood tests to measure chronic inflammation. The company's core product line, suPARnostic®, is based on the suPAR (soluble urokinase Plasminogen Activator Receptor) biomarker. This biomarker measures the activation level of the immune system to predict patient outcomes, disease risk, and the severity of chronic inflammation. The primary applications for suPARnostic® products are in hospitals for patient triaging, in the longevity market for health assessment, and in clinical research. The technology aims to improve patient care, optimize resource allocation in healthcare settings, and advance inflammation-based diagnostics.

Recent filings

Filing Released Lang Actions
ViroGates announces its first clinical routine customer in Spain
Regulatory Filings Classification · 95% confidence The document is a short company announcement (under 5,000 characters) regarding a new clinical routine customer in Spain. It follows the standard format of a regulatory news release and includes a link to the company's investor page and an attachment reference. Since it does not fit into specific categories like financial reports, M&A, or director dealings, it is classified as a general regulatory filing.
2020-04-14 English
ViroGates announces its Annual Report 2019: More than 50 hospitals are now evaluating the implementation of suPARnostic® products
Report Publication Announcement Classification · 95% confidence The document is a company announcement from ViroGates regarding the release of their Annual Report 2019. It provides a summary of financial results and business highlights but explicitly states in the text: 'This announcement is a summary and should be read in conjunction with ViroGates’ Annual Report for 2019 published on 25 March 2020.' Because the document is a short announcement (under 5,000 characters of core content) that serves to notify the market of the publication of the full report, it falls under the 'Report Publication Announcement' (RPA) category according to the 'Menu vs Meal' rule.
2020-03-25 English
ViroGates announces its Annual Report 2019: More than 50 hospitals are now evaluating the implementation of suPARnostic® products
Report Publication Announcement Classification · 95% confidence The document is a short company announcement (Company Announcement No. 6-2020) that summarizes the financial results and business highlights of ViroGates for the 2019 fiscal year. It explicitly states that it is a summary and should be read in conjunction with the full Annual Report, which is provided as an attachment. Following the 'Menu vs Meal' rule, this is an announcement of a report rather than the full 10-K/Annual Report itself.
2020-03-25 English
ViroGates announces the clinical implementation of suPARnostic® Quick Triage at hospitals in Region Zealand to be conducted by the clinical immunology department at Næstved Hospital
Regulatory Filings Classification · 95% confidence The document is a company announcement from ViroGates regarding the clinical implementation of their product, suPARnostic, in Region Zealand hospitals. It does not fit into specific categories like financial reports, board changes, or shareholder voting. As it is a general corporate announcement regarding business operations and product implementation, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate announcements.
2020-03-24 English
ViroGates announces the clinical implementation of suPARnostic® Quick Triage at hospitals in Region Zealand to be conducted by the clinical immunology department at Næstved Hospital
Regulatory Filings Classification · 95% confidence The document is a company announcement from ViroGates regarding the clinical implementation of their product, suPARnostic, at hospitals in Region Zealand. It is labeled as a 'Company Announcement' and provides details on a specific operational development rather than a financial report, audit, or governance document. Since it does not fit into specific categories like M&A, dividends, or director dealings, and is a general corporate announcement, it falls under the Regulatory Filings (RNS) category.
2020-03-24 English
ViroGates updates its strategic objectives
Regulatory Filings Classification · 90% confidence The document is a company announcement from ViroGates regarding an update to its strategic objectives and 2020 outlook due to COVID-19 and sales cycle delays. It does not constitute a full financial report, audit, or proxy statement. It is a corporate communication regarding business strategy and operational outlook, which falls under the general regulatory announcement category as it does not fit into more specific categories like earnings releases (which typically contain specific financial figures) or management reports (which are usually part of a larger annual/interim report).
2020-03-20 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.